Skip to content
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Medical Genetics

Survivorship and the Long-Term Journey with SLOS

At a Glance

Many individuals with Smith-Lemli-Opitz Syndrome (SLOS) live well into adulthood. Long-term care requires a smooth transition to adult metabolic specialists, continuous monitoring of endocrine, vision, and dental health, and ongoing management of behavioral challenges and altered pain sensation.

Thinking about the future can be daunting with a rare metabolic condition like Smith-Lemli-Opitz Syndrome (SLOS). However, medical advances mean that the outlook today is significantly different than it was a generation ago. While SLOS is a lifelong journey, many individuals with the syndrome grow into adulthood and lead meaningful lives [1].

Long-Term Outlook and Lifespan

While the risk of complications is higher in more severe cases, many individuals with SLOS survive well into adulthood [1]. The “spectrum” of the disease plays a major role here: individuals with milder forms may achieve near-normal development and independence, while those with more classic or severe symptoms will likely require lifelong support and care coordination [2][3][4].

Adulthood and Independence

For adults with SLOS, daily life often centers on maintaining a stable routine and managing neurodevelopmental challenges. Some adults may live in supported community settings or at home with family, while others with very mild forms may live independently [3]. A key challenge in adulthood can be altered pain sensation; some individuals may not feel pain the same way others do, which makes regular physical exams and safety monitoring essential to prevent undetected injuries [5].

The Lifelong Surveillance Schedule

To ensure the best possible quality of life, a “preventative” approach to health is necessary throughout adulthood. Consistent monitoring can catch issues before they become emergencies.

  • Endocrine System (Adrenal & Thyroid): Because cholesterol is used to make hormones, the risk of adrenal insufficiency remains a lifelong concern [6]. Adults must maintain their “sick-day plan” for times of illness or surgery when the body needs more stress hormones [6].
  • Vision (Retina): Monitoring for retinal peripheral avascularity (vessel issues in the eye) should continue into adulthood to prevent late-onset vision loss [7].
  • Hearing: Routine audiologic checks are necessary, as hearing loss can fluctuate or progress, impacting the ability to communicate [8].
  • Dental Health: The risk for cavities and gum disease remains high throughout life. Quarterly or bi-annual cleanings with a dentist familiar with sensory needs are recommended [9].

Managing Behavior and Sleep Over Time

The behavioral and sleep issues seen in childhood often persist or evolve over time.

Behavioral Stability

Irritability and self-injurious behaviors can remain challenges in adulthood [5]. Some adults continue to benefit from medications like simvastatin, which can help stabilize mood and reduce irritability [10]. Behavioral therapy tailored to the individual’s communication style (often utilizing their stronger receptive language skills) is also highly beneficial [11].

Sleep Quality

Sleep disturbances often track with biochemical levels. Maintaining stable cholesterol levels through diet or supplementation can help improve sleep quality, which in turn reduces daytime behavioral issues [12].

Transitioning to Adult Care

One of the most critical logistical hurdles is the transition plan. Moving from a pediatric team to adult specialists is notoriously difficult. Many metabolic clinics are housed exclusively within pediatric hospitals, meaning that finding an adult metabolic geneticist who understands SLOS can be a challenge.

Because of this, the transition process should ideally begin in the mid-teen years. Early planning ensures that the deep knowledge of the medical history is passed on accurately, preserving the stability achieved during childhood [13].

The goal of long-term care in SLOS is to transition from “surviving” the diagnosis to “thriving” within the individual’s unique potential, supported by a lifelong network of specialized care [14].

Common questions in this guide

What is the life expectancy for someone with Smith-Lemli-Opitz Syndrome?
Many individuals with SLOS survive well into adulthood. The long-term outlook largely depends on the severity of the condition, with milder cases achieving near-normal development and independence, while more severe cases require lifelong support.
Why do adults with SLOS need ongoing endocrine monitoring?
Because cholesterol is required to make essential hormones, individuals with SLOS have a lifelong risk of adrenal insufficiency. They must maintain a specific sick-day plan to manage times of illness or surgery when the body needs more stress hormones.
How does altered pain sensation affect adults with SLOS?
Some individuals with SLOS do not feel pain the way others do. This altered pain sensation means they require regular physical exams and careful safety monitoring by caregivers to ensure that injuries do not go undetected.
Can simvastatin be used for adults with SLOS?
Yes, some adults continue to benefit from medications like simvastatin. It can help stabilize mood and reduce challenging behaviors, such as irritability and self-injury, that may persist into adulthood.
When should transition planning for adult SLOS care begin?
Transition planning should ideally begin in the mid-teen years. Early planning is critical because finding an adult metabolic geneticist who understands SLOS can be challenging, and a careful handover preserves the stability achieved during childhood.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is our transition plan for moving from pediatric to adult metabolic and endocrine care?
  2. 2.How often should we repeat the ACTH stimulation test or cortisol checks in adulthood?
  3. 3.How will the cholesterol supplementation dosage change to accommodate adult weight and metabolism?
  4. 4.Are there any specific safety protocols or pain management considerations for an adult with SLOS who may have altered pain perception?
  5. 5.What adult-focused community services or housing support options are available for individuals with neurodevelopmental disabilities in our area?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    Assessing Postnatal Mortality in Smith-Lemli-Opitz Syndrome.

    Selvaraman A, Rahhal S, Bianconi S, et al.

    American journal of medical genetics. Part A 2025; (197(2)):e63875 doi:10.1002/ajmg.a.63875.

    PMID: 39271956
  2. 2

    Smith-Lemli-Opitz Syndrome with Biallelic c.1295A>G (p.Tyr432Cys) Variant in the DHCR7 Gene in a 73-Year-Old Woman: Report of the Oldest Patient.

    Yılmaz M, Bebek O, Turkyilmaz A

    Molecular syndromology 2024; (15(4)):317-323 doi:10.1159/000536343.

    PMID: 39119449
  3. 3

    Familial DHCR7 genotype presenting as a very mild form of Smith-Lemli-Opitz syndrome and lethal holoprosencephaly.

    Temple SEL, Sachdev R, Ellaway C

    JIMD reports 2020; (56(1)):3-8 doi:10.1002/jmd2.12155.

    PMID: 33204589
  4. 4

    Normal IQ is possible in Smith-Lemli-Opitz syndrome.

    Eroglu Y, Nguyen-Driver M, Steiner RD, et al.

    American journal of medical genetics. Part A 2017; (173(8)):2097-2100 doi:10.1002/ajmg.a.38125.

    PMID: 28349652
  5. 5

    Traumatic Self-Inflicted Ventricular Laceration: A Case of Smith-Lemli-Opitz Syndrome in an Adult.

    Beuschel JJ, Ng GI, Abaraoha JC, Fortuna RJ

    Cureus 2024; (16(2)):e53613 doi:10.7759/cureus.53613.

    PMID: 38449995
  6. 6

    Smith-Lemli-Opitz syndrome: clinical and biochemical correlates.

    Donoghue SE, Pitt JJ, Boneh A, White SM

    Journal of pediatric endocrinology & metabolism : JPEM 2018; (31(4)):451-459 doi:10.1515/jpem-2017-0501.

    PMID: 29455191
  7. 7

    Smith-Lemli-Optiz syndrome: importance of ophthalmology referral and follow-up.

    López-Cañizares A, Al-Khersan H, Fernandez MP, et al.

    Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus 2023; (27(2)):100-102 doi:10.1016/j.jaapos.2022.11.007.

    PMID: 36563894
  8. 8

    Auditory phenotype of Smith-Lemli-Opitz syndrome.

    Zalewski CK, Sydlowski SA, King KA, et al.

    American journal of medical genetics. Part A 2021; (185(4)):1131-1141 doi:10.1002/ajmg.a.62087.

    PMID: 33529473
  9. 9

    Smith-Lemli-Opitz Syndrome: Oral Characteristics and Risk Factors for Caries Development.

    Olczak-Kowalczyk D, Witt-Porczyk A, Piekoszewska-Ziętek P, Krajewska-Walasek M

    Biomedicines 2025; (13(3)) doi:10.3390/biomedicines13030574.

    PMID: 40149551
  10. 10

    A placebo-controlled trial of simvastatin therapy in Smith-Lemli-Opitz syndrome.

    Wassif CA, Kratz L, Sparks SE, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2017; (19(3)):297-305 doi:10.1038/gim.2016.102.

    PMID: 27513191
  11. 11

    Cross-sectional analysis of expressive and receptive language skills in Smith-Lemli-Opitz syndrome (SLOS).

    Morris SM, Tierney E

    Journal of rare diseases (Berlin, Germany) 2025; (4(1)):56 doi:10.1007/s44162-025-00119-5.

    PMID: 40979443
  12. 12

    A Pilot Study of the Association of Markers of Cholesterol Synthesis with Disturbed Sleep in Smith-Lemli-Opitz Syndrome.

    Freeman KA, Olufs E, Tudor M, et al.

    Journal of developmental and behavioral pediatrics : JDBP 2016; (37(5)):424-30 doi:10.1097/DBP.0000000000000317.

    PMID: 27244299
  13. 13

    First documented case of Smith-Lemli-Opitz syndrome in Syria: clinical presentation, diagnosis, and experimental management with simvastatin.

    Aladia AH, Hamdan S, Alkheder A

    Oxford medical case reports 2024; (2024(11)):omae129 doi:10.1093/omcr/omae129.

    PMID: 39575090
  14. 14

    Smith-Lemli-Opitz Syndrome (SLOS)-Case Description and the Impact of Therapeutic Interventions on Psychomotor Development.

    Kozera N, Śmigiel R, Rozensztrauch A

    Journal of clinical medicine 2025; (14(23)) doi:10.3390/jcm14238569.

    PMID: 41375871

This page provides educational information on long-term care and survivorship for SLOS. It is not a substitute for professional medical advice from a specialized metabolic geneticist or endocrinologist.

Get notified when new evidence is published on Smith-Lemli-Opitz syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.